Blog
RSS FeedPosted by Michael Wonder on 09 Apr 2018
NICE u-turn sees Roche’s Tecentriq backed for lung cancer
9 April 2018 - Roche starts the week on a positive note with a NICE recommendation after two rejections from ...
Posted by Michael Wonder on 07 Apr 2018
Roche cops another rejection from NICE
6 April 2018 - Second rebuttal from NICE in as many days. ...
Posted by Michael Wonder on 07 Apr 2018
New drugs: patient hope or harm?
26 March 2018 - Debate on whether new drugs are too expensive for the NHS continues to rage, and contradictory ...
Posted by Michael Wonder on 05 Apr 2018
NICE set to reject Roche's Ocrevus (ocrelizumab)
5 April 2018 - NICE has published an appraisal consultation document for ocrelizumab for the treatment of patients with relapsing ...
Posted by Michael Wonder on 03 Apr 2018
Atopic dermatitis patients to be denied NHS access to Dupixent
3 April 2018 - NICE has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis. ...
Posted by Michael Wonder on 28 Mar 2018
Final NICE green light for Ipsen’s Cometriq
28 March 2018 - Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid ...
Posted by Michael Wonder on 22 Mar 2018
What is the evidence from past NICE single-technology appraisals regarding company submissions with base-case incremental cost-effectiveness ratios of less than £10,000/QALY?
22 March 2018 - NICE has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio of less than ...
Posted by Michael Wonder on 22 Mar 2018
Resolving the “cost-effective but unaffordable” paradox: estimating the health opportunity costs of non-marginal budget impacts
22 March 2018 - Considering whether or not a proposed investment (an intervention, technology, or program of care) is affordable is ...
Posted by Michael Wonder on 22 Mar 2018
Affordability of new technologies: the next frontier
22 March 2018 - Affordability, or rather a lack of it, has become a new buzzword in health policy. It is ...
Posted by Michael Wonder on 22 Mar 2018
Harmonised health technology assessment in Europe? There’s a long way to go
22 March 2018 - Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices ...
Posted by Michael Wonder on 22 Mar 2018
Psoriasis patients get NHS access to LEO Pharma’s Kyntheum
22 March 2018 - Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the ...
Posted by Michael Wonder on 21 Mar 2018
Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies
21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs ...
Posted by Michael Wonder on 20 Mar 2018
Row over CF drug funding as NHS rejects Vertex offer
19 March 2018 - A deal covering new cystic fibrosis drugs is unlikely to happen unless the manufacturer Vertex agrees ...
Posted by Michael Wonder on 20 Mar 2018
NICE rejects rare eye disease drug
20 March 2018 - Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for ...
Posted by Michael Wonder on 19 Mar 2018
Funding breakthrough therapies: a systematic review and recommendation
17 March 2018 - Advanced therapy medicinal products are innovative therapies likely associated with high prices. ...